Andrea Pellagatti

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Year:

2025

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (8)

Richard Callaghan

Professor

University of Leeds

UNITED KINGDOM

View details

Nadege Gitego

Albert Einstein College of Medicine

UNITED STATES

View details

Michael Andreeff

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Kelly L. Bolton

UNITED STATES

View details

Tetsuichi Yoshizato

Karolinska University Hospital

SWEDEN

View details

Jacqueline Boultwood

University of Oxford

UNITED KINGDOM

View details

Hiroki Goto

Associate Professor

Kumamoto University

JAPAN

View details

Koki Ueda

Associate Professor

Fukushima Medical University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrea Pellagatti

Research Interests

Explore related searches

Contact this professor

Articles (11)

Identification of new candidate drugs in myelodysplastic syndromes with splicing factor mutations by transcriptional profiling and connectivity map analysis

ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.

BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism.

The utilisation of glutamine and glucose by a 3-D tumour model trapped in quiescence.

SF3B1 mutant myelodysplastic syndrome: Recent advances.

Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS).

Spliceosome mutations: 1 plus 1 does not always equal 2.

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Collaborators (8)

Richard Callaghan

Nadege Gitego

Michael Andreeff

Kelly L. Bolton

Tetsuichi Yoshizato

Jacqueline Boultwood

Hiroki Goto

Koki Ueda

Make your next move.